---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-007328"
form_type: "8-K"
ticker: "PULM"
cik: "0001574235"
company_name: "Pulmatrix, Inc."
filed_at: "2022-03-21T23:59:59+00:00"
generated_at: "2026-06-26T21:23:03.340580+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pulmatrix reports positive Phase 1b top-line data for PUR1800 in stable COPD

## Summary
- PUR1800 well-tolerated with no safety signals in 18-subject Phase 1b study.
- Preliminary PK shows low and consistent systemic exposure via oral inhalation.
- Company expects to advance PUR1800 to Phase 2 studies for AECOPD.
- Results to be submitted at a medical conference later in 2022.

## SEC filing metadata
- accession: 0001493152-22-007328
- form_type: 8-K
- ticker: PULM
- cik: 0001574235
- company_name: Pulmatrix, Inc.
- filed_at: 2022-03-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574235/000149315222007328/0001493152-22-007328-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574235/000149315222007328/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-007328
- JSON: https://secwatch.observer/filing/0001493152-22-007328.json
- Plain text: https://secwatch.observer/filing/0001493152-22-007328.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.